Novartis Ag

Elanco Tiergesundheit Ag

Irm LLC

Sarah Rue

Scott Glaser

Anna Galkin

Brendan P Eckelman

Quinn L Deveraux

Tetsuo Uno

Steven Lee Bender

Shailaja Kasibhatla

Bernhard Hubert Geierstanger

Marc Nasoff

Mark Knuth

Glen Spraggon

Sabine Rottmann

Tracy Charlton

Jian Shi

Steven Bruce Cohen

Jun Li

Michael DiDonato

David Langdon Yowe

Alexandra Kraus

Christian Cho-Hua Lee

Xenia Karola Wezler

Steve B Cohen

Yong Jia

Klaus Felix Hartlepp

Christoph Erkel

This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Anti-CCR7 antibody drug conjugates

Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies

This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.

Monoclonal antibodies and methods of use

Monoclonal canine CD20 antibodies and methods of use

The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a ('PCSK9') and methods of using such antibodies.

PCSK9 antagonists

Growing community of inventors

San Diego, CA, United States of America

Sarah Rue